- Home
- BREA vs CVM Comparison
BREA vs CVM Comparison
Compare BREA & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BREA
- CVM
- Stock Information
- Founded
- BREA 2022
- CVM 1983
- Country
- BREA Ireland
- CVM United States
- Employees
- BREA N/A
- CVM N/A
- Industry
- BREA Services-Misc. Amusement & Recreation
- CVM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BREA Consumer Discretionary
- CVM Health Care
- Exchange
- BREA Nasdaq
- CVM Nasdaq
- Market Cap
- BREA 16.1M
- CVM 18.1M
- IPO Year
- BREA 2023
- CVM 1987
- Fundamental
- Price
- BREA $6.55
- CVM $7.63
- Analyst Decision
- BREA
- CVM
- Analyst Count
- BREA 0
- CVM 0
- Target Price
- BREA N/A
- CVM N/A
- AVG Volume (30 Days)
- BREA 12.3K
- CVM 591.9K
- Earning Date
- BREA 01-01-0001
- CVM 08-18-2025
- Dividend Yield
- BREA N/A
- CVM N/A
- EPS Growth
- BREA N/A
- CVM N/A
- EPS
- BREA N/A
- CVM N/A
- Revenue
- BREA $2,988,009.00
- CVM N/A
- Revenue This Year
- BREA N/A
- CVM N/A
- Revenue Next Year
- BREA N/A
- CVM N/A
- P/E Ratio
- BREA N/A
- CVM N/A
- Revenue Growth
- BREA 151.51
- CVM N/A
- 52 Week Low
- BREA $5.00
- CVM $1.98
- 52 Week High
- BREA $19.50
- CVM $39.30
- Technical
- Relative Strength Index (RSI)
- BREA 48.35
- CVM 57.17
- Support Level
- BREA $6.14
- CVM $6.84
- Resistance Level
- BREA $6.75
- CVM $9.43
- Average True Range (ATR)
- BREA 0.41
- CVM 1.53
- MACD
- BREA 0.01
- CVM -0.18
- Stochastic Oscillator
- BREA 41.84
- CVM 37.05
About BREA Brera Holdings PLC
Brera Holdings PLC focused on expanding social impact football by developing a international portfolio of emerging football clubs with increased opportunities to earn tournament prizes, gain sponsorships, and provide other professional football and related consulting services.
About CVM Cel-Sci Corporation
CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development of the treatment of cancer and other diseases using the immune system. The Company's core capabilities include drug discovery, research, development, and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.